JP2021525752A5 - - Google Patents

Info

Publication number
JP2021525752A5
JP2021525752A5 JP2020566834A JP2020566834A JP2021525752A5 JP 2021525752 A5 JP2021525752 A5 JP 2021525752A5 JP 2020566834 A JP2020566834 A JP 2020566834A JP 2020566834 A JP2020566834 A JP 2020566834A JP 2021525752 A5 JP2021525752 A5 JP 2021525752A5
Authority
JP
Japan
Prior art keywords
present
activation
novel heterocyclic
stat3 protein
suppresses
Prior art date
Application number
JP2020566834A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019231271A5 (https=
JP2021525752A (ja
JP7558066B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2019/006554 external-priority patent/WO2019231271A1/en
Publication of JP2021525752A publication Critical patent/JP2021525752A/ja
Publication of JPWO2019231271A5 publication Critical patent/JPWO2019231271A5/ja
Publication of JP2021525752A5 publication Critical patent/JP2021525752A5/ja
Application granted granted Critical
Publication of JP7558066B2 publication Critical patent/JP7558066B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566834A 2018-05-31 2019-05-31 複素環誘導体及びその使用 Active JP7558066B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0062450 2018-05-31
KR20180062450 2018-05-31
PCT/KR2019/006554 WO2019231271A1 (en) 2018-05-31 2019-05-31 Heterocyclic derivatives and use thereof

Publications (4)

Publication Number Publication Date
JP2021525752A JP2021525752A (ja) 2021-09-27
JPWO2019231271A5 JPWO2019231271A5 (https=) 2022-03-31
JP2021525752A5 true JP2021525752A5 (https=) 2022-03-31
JP7558066B2 JP7558066B2 (ja) 2024-09-30

Family

ID=68698337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566834A Active JP7558066B2 (ja) 2018-05-31 2019-05-31 複素環誘導体及びその使用

Country Status (8)

Country Link
US (1) US12404249B2 (https=)
EP (1) EP3802495B1 (https=)
JP (1) JP7558066B2 (https=)
KR (1) KR102229471B1 (https=)
CN (1) CN112204010B (https=)
ES (1) ES3041067T3 (https=)
TW (1) TWI853814B (https=)
WO (1) WO2019231271A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110105237B (zh) * 2019-06-06 2021-12-24 东北师范大学 一种β-偕二氟叠氮化合物及其制备和应用
US11648254B2 (en) 2021-03-02 2023-05-16 Kumquat Biosciences Inc. Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling
CN113845476B (zh) * 2021-11-08 2024-04-30 中国药科大学 一种喹诺酮衍生物及其制备方法和用途
CN114315802B (zh) * 2021-12-14 2023-06-16 西安医学院 一种喹唑啉含氮杂环衍生物及制备方法和用途
KR20250004810A (ko) 2022-04-20 2025-01-08 컴쿼트 바이오사이언시즈 인크. 대환식 헤테로환 및 이의 용도
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
WO2001081345A1 (en) 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Aromatic amide compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2007513155A (ja) * 2003-12-04 2007-05-24 スミスクライン ビーチャム コーポレーション 新規化合物
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
EP1915377A1 (en) 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
US20090170847A1 (en) 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
US20090004185A1 (en) * 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
ES2401550T3 (es) 2008-02-28 2013-04-22 Merck Patent Gmbh Inhibidores de proteína cinasa y uso de los mismos
CN102099352B (zh) 2008-07-10 2014-02-26 一般社团法人创药分子Ip 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂
WO2010036629A2 (en) * 2008-09-26 2010-04-01 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
EP2346868B1 (en) 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
NZ595087A (en) * 2009-02-11 2013-03-28 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
WO2012079079A1 (en) * 2010-12-10 2012-06-14 President And Fellows Of Harvard College Production of induced pluripotent stem cells
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
MX2020002183A (es) * 2017-08-31 2020-10-05 Abbvie Inc Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2021525752A5 (https=)
JOP20210001B1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
PH12020551205A1 (en) Fap inhibitors
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
EA202192910A1 (ru) Соединения, направленные на белки, и содержащие их фармацевтические композиции, и их терапевтическое применение
GEAP202215671A (en) Microbiocidal thiazole derivatives
BR112018072542A2 (pt) derivados de piridiniltriazol substituído com amida e usos dos mesmos
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
MX2019012445A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
PE20191243A1 (es) Nuevos derivados de fenilo
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
SA521422467B1 (ar) مركبات هالو-آلِّيلامين واستخدامها
JOP20210127A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
JP2018186833A5 (https=)
JOP20210034A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
SG11202011427XA (en) Fish protein hydrolysate powder and a composition comprising said powder for use as a medicament
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos
HUE066894T2 (hu) Triszamid vegyületek és azokat tartalmazó készítmények